Rejuvenate Bio

I am excited to be presenting Charles River Laboratories Gene Therapy Summit. https://bit.ly/4aLCa3U??#CGTSummit #cellandgenetherapy #advancedtherapies #concepttocure?

Our CEO & Co-Founder Daniel Oliver was on the cell and gene therapy panel at Biotech Showcase during #JPM25 last week moderated by journalist David Ewing Duncan. Cell & Gene Therapy: Moving Beyond Discovery and Into the Patient Paul Bresge - CEO, Ray Therapeutics, Inc. Daniel Oliver - CEO, Rejuvenate Bio Nabiha Saklayen - CEO & Founder, Cellino Lexi Rovner - CEO, 64x Bio ???Ohad Karnieli - Founder & CEO , Adva Biotechnology Great seeing everyone there!

Will you be at JPM next week? We’re honored to?host a CEO Roundtable discussion at?WuXi?AppTec’s #WuXiGlobalForum alongside #JPM2025. The event will highlight how every innovation story matters. Looking forward to the discussions.?https://lnkd.in/ggH5Weqf

CEO Daniel Oliver will be in SF next week and will be speaking on the EBD Group panel on new innovations in gene therapy. #BiotechShowcase #genetherapy

Really excited to be working with Haolin Sung and the rest of the amazing Protect Animal Health Inc. team!!

CIRM awarded $4 million to support the development of a one-time gene therapy for desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). This funding supports Deborah Ascheim, MD, and her team at?Rejuvenate Bio?in advancing RJB-0402, a therapy designed to address the root causes of DSP ACM. DSP ACM arises from a mutation in the DSP gene, leading to irregular heartbeats and potential heart failure over time. RJB-0402 uses AAV8 to deliver the gene responsible for producing the FGF21 protein, which supports heart function and mitigates issues common in DSP ACM. This award will help transition the therapy into clinical trials, providing a new treatment avenue for patients in need.

Our CEO Daniel Oliver spoke on a panel on Commercialization Strategies for Biotechs and Early Planning at the LSX USA Congress in Boston. Great meeting everyone and see you all at the next event!

Our CEO, Travis Stiles, will be part of a panel at this upcoming BioLife Summits event. We are grateful to have been invited to participate in such an incredible line-up of speakers, representing the fantastic local biotech and life science ecosystem. We look forward to sharing our insights with all who can make it. #lifesciences #leadership #biotech #biotechinnovation

There is a surprisingly large gap in the U.S. between average years lived (76.4) and average years lived in good health (63.9). It's estimated that 95% of U.S. adults aged 60 and older have a chronic disease and 80% have two or more. Facing a growing demographic of unhealthy seniors, innovative biotechs are reframing the longevity discussion: Rather than treat the symptoms of aging one disease at a time, what if we could instead focus on the root causes, enabling treatment of multiple chronic diseases simultaneously? Read our most recent cover story to learn more about the exciting potential of gene therapies and epigenetics in age-related disease. https://lnkd.in/gSq3gD6F Thank you to Daniel Oliver at Rejuvenate Bio, Jennifer B. Kwon at Tune Therapeutics and Dr. Thomas Solbach at Strategy& for your helpful insights! #epigenetics #genetherapy #antiaging #longevity

BioProcess International speaks with our CEO & Co-Founder Daniel Oliver about our $4M CIRM grant and what’s next for the company. ???? Gene-therapy developer Rejuvenate Bio was recently awarded $4 million by the California Institute for Regenerative Medicine (CIRM) to pursue investigational new drug (IND) activities for RJB-0402 to treat desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). Rejuvenate Bio will use the funds to perform confirmatory animal studies in mice and non-human primates; support manufacturing scale-up through helping attain representative good manufacturing practice (GMP) materials; and perform patient outreach. Read the article: https://lnkd.in/exviT_pe